While most of these proteins have proven their applicability in diagnosing certain pathologies, e.g. the early detection of prostate cancer (PSA) or the monitoring of colorectal cancer treatment (CEA), they often lack clinical specificity [39], [40], [41]. This evidence concerns the gene KLK3 and prostate carcinoma.